זיפרקסה ולוטב 10 מג ישראל - עברית - Ministry of Health

זיפרקסה ולוטב 10 מג

eli lilly israel ltd, israel - olanzapine - טבליות מסיסות בפה - olanzapine 10 mg - olanzapine - olanzapine - acute and maintenance treatment of schizophrenia. zyprexa is indicated for the management of the manifestations of psychotic disorders. zyprexa is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder : in patients whose manic episode has responded to olanzapine treatment zyprexa is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of zyprexa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

זיפאדהרה 210 מ"ג ישראל - עברית - Ministry of Health

זיפאדהרה 210 מ"ג

eli lilly israel ltd - olanzapine 210 mg - powder for suspension for injection - olanzapine - zypadhera is indicated for the treatment of schizophrenia.the use of zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .zypadhera is not to be used in patients whose condition is adequately controlled with oral zyprexa .zypadhera is available only through a restricted program which will be conducted according to zypadhera eu risk management plan.for a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the zypadhera risk management plan. the zypadhera risk management plan has been developed to enable the safe use of zypadhera in patients, including the management of those patients who develop post-injection delirium and sedation syndrome. in addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr

זיפאדהרה 300 מ"ג ישראל - עברית - Ministry of Health

זיפאדהרה 300 מ"ג

eli lilly israel ltd - olanzapine 300 mg - powder for suspension for injection - olanzapine - zypadhera is indicated for the treatment of schizophrenia.the use of zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .zypadhera is not to be used in patients whose condition is adequately controlled with oral zyprexa .zypadhera is available only through a restricted program which will be conducted according to zypadhera eu risk management plan.for a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the zypadhera risk management plan. the zypadhera risk management plan has been developed to enable the safe use of zypadhera in patients, including the management of those patients who develop post-injection delirium and sedation syndrome. in addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr

זיפאדהרה 405 מ"ג ישראל - עברית - Ministry of Health

זיפאדהרה 405 מ"ג

eli lilly israel ltd - olanzapine as pamoate monohydrate 405 mg - powder for suspension for injection - olanzapine - zypadhera is indicated for the treatment of schizophrenia.the use of zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .zypadhera is not to be used in patients whose condition is adequately controlled with oral zyprexa .zypadhera is available only through a restricted program which will be conducted according to zypadhera eu risk management plan.for a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the zypadhera risk management plan. the zypadhera risk management plan has been developed to enable the safe use of zypadhera in patients, including the management of those patients who develop post-injection delirium and sedation syndrome. in addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr

יינטריב 20 מג ישראל - עברית - Ministry of Health

יינטריב 20 מג

eli lilly israel ltd, israel - duloxetine as hydrochloride - קפסולות - duloxetine as hydrochloride 20 mg - duloxetine - duloxetine - yentreve is indicated for women for the treatment of moderate to severe stress urinary incontinence (sui).

יינטריב 40 מג ישראל - עברית - Ministry of Health

יינטריב 40 מג

eli lilly israel ltd, israel - duloxetine as hydrochloride - קפסולות - duloxetine as hydrochloride 40 mg - duloxetine - duloxetine - yentreve is indicated for women for the treatment of moderate to severe stress urinary incontinence (sui).

סימבאלתה 30 מג ישראל - עברית - Ministry of Health

סימבאלתה 30 מג

eli lilly israel ltd - duloxetine as hydrochloride - capsules - duloxetine as hydrochloride 30 mg - duloxetine - duloxetine - - cymbalta is indicated for the treatment of major depressive episodes. - cymbalta is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy. - cymbalta is indicated for the treatment of generalized anxiety disorder (gad).- cymbalta is indicated for the management of fibromyalgia.- cymbalta is indicated for the management of chronic muscoskeletal pain. this has been established is studies in patients with chronic low back pain and chronic pain due to osteoarthritis when other therapies have failed or are contra-indicated.

סימבאלתה 60 מג ישראל - עברית - Ministry of Health

סימבאלתה 60 מג

eli lilly israel ltd - duloxetine as hydrochloride - capsules - duloxetine as hydrochloride 60 mg - duloxetine - duloxetine - - cymbalta is indicated for the treatment of major depressive episodes. - cymbalta is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy. - cymbalta is indicated for the treatment of generalized anxiety disorder (gad).- cymbalta is indicated for the management of fibromyalgia.- cymbalta is indicated for the management of chronic muscoskeletal pain. this has been established is studies in patients with chronic low back pain and chronic pain due to osteoarthritis when other therapies have failed or are contra-indicated..

גמזר 200 מג ישראל - עברית - Ministry of Health

גמזר 200 מג

eli lilly israel ltd - gemcitabine as hydrochloride - אבקה מיובשת בהקפאה להכנת תרכיז לאינפוזיה - gemcitabine as hydrochloride 200 mg/vial - pyrimidine analogues - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

גמזר 200 מג ישראל - עברית - Ministry of Health

גמזר 200 מג

eli lilly israel ltd - gemcitabine as hydrochloride - אבקה מיובשת בהקפאה להכנת תרכיז לאינפוזיה - gemcitabine as hydrochloride 200 mg/vial - pyrimidine analogues - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.